A-86929 is a synthetic compound that acts as a selective dopamine receptorD1agonist. It was developed as a possible treatment for Parkinson's disease, as well as for other applications such as treatment of cocaine addiction, but while it had reasonable efficacy in humans it also caused dyskinesias and has not been continued. It has mainly been used as its diacetateesterprodrugadrogolide (ABT-431), which has better bioavailability.
Yields on 10-year bonds were up 7 basis points (bps) at 2.86%, after hitting 2.929%, their highest since October 2023. They jumped more than 30bps on Wednesday, recording the biggest daily rise since May 1997... Reuters .
